BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 14, 2009
View Archived Issues
Heed All FDA Compliance Efforts, Drugmakers Warned by Panelists
Read More
Amarin's $70M: 'Mixing' It up Against Lovaza in Lipid Space
Read More
Corcept Raising $18M to Push Corlux Through Final Testing
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Vanda Inks $465M Novartis Deal, but Acquisition Not off the Table
Five months after the surprise FDA approval of schizophrenia drug Fanapt (iloperidone), Vanda Pharmaceuticals Inc. nailed down a partner to launch the product. (BioWorld Today)
Read More
Prosensa, GSK: $25M Up Front, Antisense to Make DMD Sense?
Read More